Biblio

Author Title [ Type

] Year

Filters: Author is Ghesquières, Hervé [Clear All Filters]

Journal Article

Fruchart C, Tilly H, Morschhauser F, Ghesquières H, Bouteloup M, Fermé C, Van Den Neste E, Bordessoule D, Bouabdallah R, Delmer A, et al. Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B-Cell Lymphoma. Biol Blood Marrow Transplant. 2014.

Zinzani PLuigi Luig, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto LMaria, Garcia-Sancho AMartin, Christian B, Gulbas Z, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170. Blood. 2023.

Manson G, Mear J-B, Herbaux C, Schiano J-M, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, et al. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer. 2019;115:47-56.

Younan N, Soussain C, Choquet S, Cassoux N, Touitou V, Schmitt A, Chinot O, Obéric L, Damaj G, Houot R, et al. Isolated intraocular relapses of primary cerebral lymphomas: AN LOC NETWORK STUDY. Hematol Oncol. 2022.

Stathis A, Pirosa MCristina, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FGaia, Merli F, Guieze R, et al. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. Haematologica. 2024.

Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Am J Hematol. 2018.

Sesques P, Bourcier J, Golfier C, Lebras L, Nicolas-Virelizier E, Hacini M, Perrin MClaire, Voillat L, Bachy E, Traverse-Glehen A, et al. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Hematol Oncol. 2020.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Díez-Martín JL, Corradini P, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer. 2018.

Ghesquières H, Dalban C, Nicolas-Virelizier E, Jardin F, Le Bras F, Le Gouill S, Casasnovas O, Vizoso S, Hernandez C, Metzger S, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres. Br J Haematol. 2021.